What is HPT Pharma?
Based in the United States, HPT Pharma operates as a critical provider of blister packaging tooling and precision engineering solutions. With a legacy spanning over 25 years, the organization serves a diverse clientele ranging from large-scale pharmaceutical manufacturers to contract packaging organizations and clinical trial entities. The company distinguishes itself through rapid lead times and robust in-house CNC machining capabilities, which are essential for maintaining the rigorous quality standards required in the nutraceutical and pharmaceutical supply chains. By focusing on cost-effective, innovative design, HPT Pharma remains a pivotal partner for firms seeking to optimize their packaging workflows and ensure regulatory compliance.
How much funding has HPT Pharma raised?
HPT Pharma has raised a total of $932K across 2 funding rounds:
Debt
$350K
Debt
$582K
Debt (2020): $350K with participation from PPP
Debt (2021): $582K led by PPP
Key Investors in HPT Pharma
PPP
Public-Private Partnership
What's next for HPT Pharma?
With the recent influx of capital, HPT Pharma is well-positioned to accelerate its technological roadmap and expand its manufacturing footprint. The strategic focus will likely shift toward further automating its CNC machining processes and reducing lead times to meet the increasing demand for clinical trial packaging. As the pharmaceutical industry continues to prioritize supply chain resilience, HPT Pharma's ability to provide high-quality, timely tooling will be a key driver of its long-term growth trajectory. Future initiatives will likely involve scaling production capacity to support larger enterprise-level contracts, thereby cementing its status as a leader in the specialized packaging tooling market.
See full HPT Pharma company page
